Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 7/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | CCR2 | P41597 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8402885 | 0.87 | BCHE (0.59) | BCHESMN1; SMN2KDM2B | |
| SCHEMBL26999697 | 0.85 | BCHE (0.52) | BCHESMN1; SMN2KDM2BHSD11B1CCR2 | |
| SCHEMBL24777711 | 0.85 | BCHE (0.68) | BCHESMN1; SMN2KDM2BHSD11B1CCR2 | |
| SCHEMBL8820146 | 0.85 | BCHE (0.52) | BCHESMN1; SMN2KDM2BHSD11B1CCR2 | |
| SCHEMBL441659 | 0.83 | BCHE (0.69) | BCHESMN1; SMN2KDM2BHSD11B1CCR2 | |
| SCHEMBL21486158 | 0.82 | TSHR (0.57) | BCHESMN1; SMN2KDM2BHSD11B1CCR2 | |
| SCHEMBL15998502 | 0.81 | BCHE (0.67) | BCHESMN1; SMN2KDM2BHSD11B1ALDH1A1 | |
| SCHEMBL3936335 | 0.81 | BCHE (0.67) | BCHESMN1; SMN2KDM2BHSD11B1ALDH1A1 | |
| SCHEMBL740141 | 0.79 | SMN1; SMN2 (0.54) | BCHESMN1; SMN2KDM2BHSD11B1ALDH1A1 | |
| SCHEMBL1609328 | 0.79 | SMN1; SMN2 (0.54) | BCHESMN1; SMN2KDM2BHSD11B1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501514-B1 | PROTEIN KINASE MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2012-12-19 | — | — | EP | disclosed |
| US-7704995-B2 | Protein kinase modulators and methods of use | EXELIXIS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| EP-1501514-A4 | PROTEIN KINASE MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2009-08-26 | — | — | EP | disclosed |
| US-20060211709-A1 | Protein kinase modulators and methods of use | EXELIXIS, INC. | 2006-09-21 | — | — | US | disclosed |
| EP-1501514-A2 | PROTEIN KINASE MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2005-02-02 | — | — | EP | disclosed |
| WO-2003093297-A2 | PROTEIN KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211709-A1 | Protein kinase modulators and methods of use | GRK2, MAP4K2, MAPKAPK2 | BCHE 4237/4885SMN1; SMN2 4557/4885KDM2B 3165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.